ArticleClinical ophthalmology (Auckland, N.Z.)2019
Efficacy and safety of tafluprost 0.0015% - retrospective analysis of real-world data from the Philippines.
Article in Clinical ophthalmology (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.BMC ophthalmology · 2022Trial
- Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study.International journal of ophthalmology · 2023Article
- A Pooled Assessment of Ocular Surface Disease After Switching from Preserved Prostaglandins to Tafluprost Across Six Countries in Asia.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience.Journal of ophthalmology · 2022Article
- Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the IOP lowering effect and safety of tafluprost 0.0015% in a routine clinical setting in the Philippines. PATIENTS AND
methodsA retrospective review of glaucoma patients receiving tafluprost 0.0015% (BAK 0.001% preserved) with a minimum follow-up of 3 months was conducted. Main outcome measure was the mean IOP change at month 3. Secondary outcome measures included longitudinal IOP assessments and occurrence of any adverse events.
resultsThree-hundred twenty-nine eyes of 177 patients with mean age 64.8 years were included and followed for mean 8.8 months. Most common diagnosis was primary open-angle glaucoma (POAG) (34.9%), followed by primary angle-closure (PAC) glaucoma post-laser iridotomy (24.0%), PAC post-laser iridotomy (15.5%), ocular hypertension (OHT)(14.6%), secondary glaucoma (6.7%), and normal-tension glaucoma (4.3%). Mean IOP change at month 3 was -6.18 mmHg (SD 4.06), a -26.37% reduction (
conclusionTafluprost was a safe and effective IOP-lowering treatment in this routine clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.